UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Oct

15

Powering the dreams of people impacted by myasthenia gravis (MG)

Read More Share:linkedin| twitter| email

Oct

15

UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia gravis in the U.S.

Read More Share:linkedin| twitter| email

Oct

14

UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)

Read More Share:linkedin| twitter| email

Oct

11

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

Read More Share:linkedin| twitter| email

Sep

30

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

Read More Share:linkedin| twitter| email

Sep

27

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

Read More Share:linkedin| twitter| email

Sep

25

UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

Read More Share:linkedin| twitter| email

Sep

23

UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Read More Share:linkedin| twitter| email

Sep

23

Redefining Immunology Care: Our Pledge to Patients and the Healthcare Community

Read More Share:linkedin| twitter| email

Sep

16

UCB and BlackDoctor.org Bring Nation’s Top Health Equity Leaders Together to Discuss Access Issues in Third Annual Health Equity Expo

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)